↓ Skip to main content

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

Overview of attention for article published in Acta Neuropathologica Communications, June 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial
Published in
Acta Neuropathologica Communications, June 2014
DOI 10.1186/2051-5960-2-68
Pubmed ID
Authors

Vincent Peter Collins, Koichi Ichimura, Ying Di, Danita Pearson, Ray Chan, Lindsay C Thompson, Rhian Gabe, Michael Brada, Sally P Stenning

Abstract

We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy.354 samples (79.2%) from the first operation of the 447 randomised patients provided enough tumour DNA for some or all parts of the study. Genome-wide array comparative genomic hybridisation (aCGH), mutation analysis of IDH1/2 and TP53 and methylation analyses of the MGMT CpG-island was done.84% of grade III tumours and 17% of grade IV had IDH1 or IDH2 mutations that conferred a better prognosis in both; MGMT methylation (defined as average value across 16 CpGs ≥ 10%) occurred in 75% of tumours and was also associated with improved survival. Both were of independent prognostic value after accounting for clinical factors and tumour grade. None of the molecular changes investigated gave clear evidence of a predictive benefit of TMZ over PCV or 21-day TMZ over 5-day TMZ although power was limited and a role for MGMT methylation could not be ruled out. Loss of 1p and 19q was seen in only 4 patients although hemizygous loss of 1p36 occurred in 20%.The findings support reports that IDH1/2 mutations and MGMT methylation can be used in addition to tumour grade and clinical factors to predict survival in patients with recurrent high grade gliomas when treated with any of the therapy regimes used.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
United States 1 3%
Brazil 1 3%
Unknown 33 92%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 17%
Student > Doctoral Student 6 17%
Researcher 5 14%
Student > Ph. D. Student 4 11%
Student > Postgraduate 3 8%
Other 7 19%
Unknown 5 14%
Readers by discipline Count As %
Medicine and Dentistry 15 42%
Neuroscience 3 8%
Agricultural and Biological Sciences 3 8%
Nursing and Health Professions 2 6%
Biochemistry, Genetics and Molecular Biology 2 6%
Other 5 14%
Unknown 6 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2014.
All research outputs
#7,179,451
of 12,440,396 outputs
Outputs from Acta Neuropathologica Communications
#353
of 564 outputs
Outputs of similar age
#83,926
of 194,233 outputs
Outputs of similar age from Acta Neuropathologica Communications
#6
of 12 outputs
Altmetric has tracked 12,440,396 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 564 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,233 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.